<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/89E34DE7-2BDA-4343-9708-C5BD3FD1A7CB"><gtr:id>89E34DE7-2BDA-4343-9708-C5BD3FD1A7CB</gtr:id><gtr:name>Janssen Biotech</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2CFA3CCE-D7B5-4E91-8299-47E773A16C97"><gtr:id>2CFA3CCE-D7B5-4E91-8299-47E773A16C97</gtr:id><gtr:name>Abbvie</gtr:name><gtr:address><gtr:line1>1 North Waukegan Road</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AA7CF37A-1A3C-4DC6-8488-4445B285ACA2"><gtr:id>AA7CF37A-1A3C-4DC6-8488-4445B285ACA2</gtr:id><gtr:name>Genentech</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>William Harvey Research Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/89E34DE7-2BDA-4343-9708-C5BD3FD1A7CB"><gtr:id>89E34DE7-2BDA-4343-9708-C5BD3FD1A7CB</gtr:id><gtr:name>Janssen Biotech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2CFA3CCE-D7B5-4E91-8299-47E773A16C97"><gtr:id>2CFA3CCE-D7B5-4E91-8299-47E773A16C97</gtr:id><gtr:name>Abbvie</gtr:name><gtr:address><gtr:line1>1 North Waukegan Road</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AA7CF37A-1A3C-4DC6-8488-4445B285ACA2"><gtr:id>AA7CF37A-1A3C-4DC6-8488-4445B285ACA2</gtr:id><gtr:name>Genentech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/81E455DE-3436-49A5-B2A8-B6ABDCB8D837"><gtr:id>81E455DE-3436-49A5-B2A8-B6ABDCB8D837</gtr:id><gtr:firstName>Costantino</gtr:firstName><gtr:surname>Pitzalis</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DB9EFB9A-C5B8-463F-966C-E407D0CD4D37"><gtr:id>DB9EFB9A-C5B8-463F-966C-E407D0CD4D37</gtr:id><gtr:firstName>Ernest</gtr:firstName><gtr:surname>Choy</gtr:surname><gtr:orcidId>0000-0003-4459-8609</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EEE5331C-7D11-4578-BAC5-788C990A6C47"><gtr:id>EEE5331C-7D11-4578-BAC5-788C990A6C47</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>McInnes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/16B653E2-0DEA-4EC3-BEB0-B755754726BD"><gtr:id>16B653E2-0DEA-4EC3-BEB0-B755754726BD</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Buckley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0D1BB1B6-A7EC-4CE0-942B-734C4A958A34"><gtr:id>0D1BB1B6-A7EC-4CE0-942B-734C4A958A34</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800648"><gtr:id>B4A247B0-F984-42E3-A0E4-8869B56292AB</gtr:id><gtr:title>Pathobiology of Early Arthritis Cohort (PEAC)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800648</gtr:grantReference><gtr:abstractText>Rheumatoid arthritis (RA) is a diverse disease with some patients suffering from a mild disease while others develop a more aggressive course. At present it is impossible to predict from the outset the final disease outcome. Expert opinion favours the use of aggressive treatment in all patients with early RA including the use of the new biological agents (magic bullets). Given the high costs of these drugs (#10,000/year/patient) and their potential toxicity it is imperative to tailor early treatment to patients most at risk of poor outcome. 

In some other inflammatory conditions such as kidney diseases specific treatments are guided by the severity of the tissue pathology determined following examination of the tissue under the microscope. We propose to validate and use the same concept to treat patients with RA. Patients would have a small piece of tissue (synovial biopsy) taken from the joint at disease outset that will be analysed for specific features that might give clues on the severity of the disease enabling doctors to target specific therapies to those most in need. 

This together with studying biological markers in the blood and urine of these patients will enable scientist to investigate potential causes regarding the origin, evolution and treatment of arthritis. 

It is hoped that the elucidation of key pathways involved in the perpetuation or resolution of inflammation will lead to the development of new drugs (and/or the testing currently available drugs in a better way) that will facilitate induction of remission in the majority of patients. This in turn will result in less joint damage and consequent disability with considerable alleviation of suffering for patients and their family as well as reduction of the health-economic burden on the NHS and society in general.</gtr:abstractText><gtr:technicalSummary>Rheumatoid arthritis (RA) is one of the most important chronic inflammatory disorders in the UK. It affects approximately 1% of adults, causes considerable morbidity, reduces quality of life, increases mortality and results in large medical costs (over #1.2 billion/year). Importantly, RA behaves clinically as a heterogeneous condition with a variable clinical course and major differences in joint damage scores and consequent disability. Thus, it is crucial to tailor potentially toxic and expensive drugs (biologic #10k/year/patient/) to the individual patient?s needs as well as for targeting limited health care resources. Current prognostic algorithms are insufficiently sensitive at presentation to reliably identify individuals that will progress to destructive arthritis and hence functional and economic decline. 

The purpose of the application is to address this unmet clinical need by developing a prospective cohort of early inflammatory arthritis patients with the goal of creating a unique resource with high-density data including genotyping, biologic tissue characterisation, state?of-the-art 3/4D ultrasound-US/power-Doppler-PDU imaging, and detailed clinical phenotyping that will enable us to search for early predictors of disease evolution as well as to examine the role of multiple cellular and molecular pathways involved in joint destruction and therapeutic response. 

Thus, this cohort will represent an ideal platform for innovative clinical trials with stratified entry according to imaging, biologic and clinical profile that will be of major interest to academia, industry and government bodies. In particular, it is envisaged that time integrated US/PDU imaging will improve on currently employed composite clinical assessment tools permitting earlier evaluation of response to therapy and development of novel prognostic algorithms of structural damage progression. Equally, the comprehensive collection of samples (particularly synovial tissue through a US guided minimally invasive biopsy) will facilitate research in the fields of Genomics, Transcriptomics, Proteomics, Metabonomics, Cell and Humoral Biology enabling scientists to test and generate hypotheses on the disease origin, susceptibility and diverse outcome. 

Despite being a common disease there have been few cohorts in the UK that have systematically collected clinical, radiological, genetic and biological data. The Pathobiology of Early Arthritis Cohort (PEAC) will provide such a unified approach. It will lead to a step change in the way in which clinical, imaging and immune-pathologic data is collated and integrated in the UK, allowing UK rheumatologists to have a unique resource to compete within the EU arena, where complementary but distinct approaches in the Netherlands and Scandinavia have proven to be highly informative and successful.</gtr:technicalSummary><gtr:fund><gtr:end>2014-04-01</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>564577</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Metabolic analysis in serum and urine of patients with early arthritis</gtr:description><gtr:id>3E65FD8E-F828-4155-BC20-AB25240A0A1D</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:partnerContribution>Metabolomic analysis of samples to identify biomarkers in early arthritis</gtr:partnerContribution><gtr:piContribution>Provided samples and data from the PEAC cohort</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AbbVie</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>AbbVie: Targeting synovial tissue pathways in RA patients resistant to conventional DMARDs: screening AbbVie development pipeline.</gtr:description><gtr:id>392E85E1-0BDD-4B32-97AD-15C8F07CB6BE</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:partnerContribution>Financial support &amp;amp; pipeline compounds</gtr:partnerContribution><gtr:piContribution>Analysis of samples</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PEAC Consortium</gtr:description><gtr:id>D7CD6278-DCE9-4403-B69F-0AB8438F2D86</gtr:id><gtr:impact>Multiple publications, which are continuing to be generated.
Additional academic and industry partnerships 
Additional grant funding secured 
Additional industry funding secured 
Change in policy regarding support for research on stratified medicines 
Patents pending</gtr:impact><gtr:partnerContribution>Partners provided samples to generate this unique bio-medical resource with high-density data including gene expression profiling, proteomics, metabonomics, genotyping, serum and synovial fluid cyotokine &amp;amp; chemokine analysis, biological tissue characterisation, state-of-the-art ultrasound imaging, and detailed clinical phenotyping. This resource continues to enable assessment of the role of a spectrum of molecular and cellular pathways that may be involved in disease susceptibility, heterogeneity and treatment response.</gtr:partnerContribution><gtr:piContribution>The PEAC Initiative was led and coordinated by Professor Costantino Pitzalis with the support of the members of the PEAC consortium, the PEAC Steering Committee and the PEAC Scientific Advisory Board.

In order to ensure effective and efficient administration of the PEAC project, the following administrative infrastructure was installed:

Project Management: to ensure optimal coordination and administration of this programme together with timely and high quality data collection and analysis.

Technical Assistance: A highly experience and able Research Assistant, Miss Rebecca Hands was appointed to ensure efficient processing, storing and high fidelity archiving of PEAC biological samples.

Data Management: A website was created to act as a central repository for all the PEAC project samples and their related data.

Over 300 patients were recruited for the study at Bart's</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>MedImmune</gtr:department><gtr:description>MedImmune / AZ: MRC/MICA Targeting IL-21 in specific synovial tissue pathotypes</gtr:description><gtr:id>30CCC516-908E-4AB3-9345-5D1AFE4E2ABF</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:partnerContribution>Financial support</gtr:partnerContribution><gtr:piContribution>Analysis of synovial samples</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PEAC Consortium</gtr:description><gtr:id>3BA4D5DF-E2B1-434D-A9F8-51115F48617F</gtr:id><gtr:impact>Multiple publications, which are continuing to be generated.
Additional academic and industry partnerships 
Additional grant funding secured 
Additional industry funding secured 
Change in policy regarding support for research on stratified medicines 
Patents pending</gtr:impact><gtr:partnerContribution>Partners provided samples to generate this unique bio-medical resource with high-density data including gene expression profiling, proteomics, metabonomics, genotyping, serum and synovial fluid cyotokine &amp;amp; chemokine analysis, biological tissue characterisation, state-of-the-art ultrasound imaging, and detailed clinical phenotyping. This resource continues to enable assessment of the role of a spectrum of molecular and cellular pathways that may be involved in disease susceptibility, heterogeneity and treatment response.</gtr:partnerContribution><gtr:piContribution>The PEAC Initiative was led and coordinated by Professor Costantino Pitzalis with the support of the members of the PEAC consortium, the PEAC Steering Committee and the PEAC Scientific Advisory Board.

In order to ensure effective and efficient administration of the PEAC project, the following administrative infrastructure was installed:

Project Management: to ensure optimal coordination and administration of this programme together with timely and high quality data collection and analysis.

Technical Assistance: A highly experience and able Research Assistant, Miss Rebecca Hands was appointed to ensure efficient processing, storing and high fidelity archiving of PEAC biological samples.

Data Management: A website was created to act as a central repository for all the PEAC project samples and their related data.

Over 300 patients were recruited for the study at Bart's</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PEAC Genotypic analysis of Methotrexate responsiveness</gtr:description><gtr:id>6860FCB6-FBAA-4DC2-A4E5-F3B0B5709C94</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:partnerContribution>Genetic analysis including methylation studies</gtr:partnerContribution><gtr:piContribution>Provided DNA samples from MTX responders and non-responders for analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rheumatology NHSGGC</gtr:department><gtr:description>Optimal Treatment of RA Patients Requiring Biologic Therapy (ORBIT).</gtr:description><gtr:id>1B763717-448D-4C48-8341-33161FA6CADE</gtr:id><gtr:impact>Results to be published</gtr:impact><gtr:partnerContribution>Expanded the opportunity of translational research by facilitating the clinical utility of synovial biopsy in a clinical trial.</gtr:partnerContribution><gtr:piContribution>Arthritis research UK has also funded a randomised clinical trial in which patients with RA that require commencement of a biologic agent by virtue of current disease activity will receive either a B cell depleting agent or a TNF blocking agent: Optimal Treatment of RA Patients Requiring Biologic Therapy (ORBIT). The PEAC investigators are part of this wider study and have nested within it an exploratory evaluation (PEAC 2) in which synovial biopsies will be used to determine whether the synovial pathotype, in particular that containing either an inflammatory or B cell dominant phenotype, enriches subsequent responsiveness to either biologic intervention. This study will capitalize upon the unique resource created by PEAC in that responses can be compared with the wider natural progression of RA patients on conventional therapy.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janssen Biotech</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Janssen / J&amp;amp;J: Genetic and genomic profiling of RA early arthritis patients</gtr:description><gtr:id>7D122713-11D4-456B-B817-5896D94D9E54</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:partnerContribution>Financial support</gtr:partnerContribution><gtr:piContribution>Analysis of samples in PEAC cohort</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PEAC Consortium</gtr:description><gtr:id>FC68A46A-F5DE-4BBC-993F-E4557A0D36BB</gtr:id><gtr:impact>Multiple publications, which are continuing to be generated.
Additional academic and industry partnerships 
Additional grant funding secured 
Additional industry funding secured 
Change in policy regarding support for research on stratified medicines 
Patents pending</gtr:impact><gtr:partnerContribution>Partners provided samples to generate this unique bio-medical resource with high-density data including gene expression profiling, proteomics, metabonomics, genotyping, serum and synovial fluid cyotokine &amp;amp; chemokine analysis, biological tissue characterisation, state-of-the-art ultrasound imaging, and detailed clinical phenotyping. This resource continues to enable assessment of the role of a spectrum of molecular and cellular pathways that may be involved in disease susceptibility, heterogeneity and treatment response.</gtr:partnerContribution><gtr:piContribution>The PEAC Initiative was led and coordinated by Professor Costantino Pitzalis with the support of the members of the PEAC consortium, the PEAC Steering Committee and the PEAC Scientific Advisory Board.

In order to ensure effective and efficient administration of the PEAC project, the following administrative infrastructure was installed:

Project Management: to ensure optimal coordination and administration of this programme together with timely and high quality data collection and analysis.

Technical Assistance: A highly experience and able Research Assistant, Miss Rebecca Hands was appointed to ensure efficient processing, storing and high fidelity archiving of PEAC biological samples.

Data Management: A website was created to act as a central repository for all the PEAC project samples and their related data.

Over 300 patients were recruited for the study at Bart's</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PEAC Consortium</gtr:description><gtr:id>F0EB5D3F-2A61-45D4-9BEC-6449AB3F7E4C</gtr:id><gtr:impact>Multiple publications, which are continuing to be generated.
Additional academic and industry partnerships 
Additional grant funding secured 
Additional industry funding secured 
Change in policy regarding support for research on stratified medicines 
Patents pending</gtr:impact><gtr:partnerContribution>Partners provided samples to generate this unique bio-medical resource with high-density data including gene expression profiling, proteomics, metabonomics, genotyping, serum and synovial fluid cyotokine &amp;amp; chemokine analysis, biological tissue characterisation, state-of-the-art ultrasound imaging, and detailed clinical phenotyping. This resource continues to enable assessment of the role of a spectrum of molecular and cellular pathways that may be involved in disease susceptibility, heterogeneity and treatment response.</gtr:partnerContribution><gtr:piContribution>The PEAC Initiative was led and coordinated by Professor Costantino Pitzalis with the support of the members of the PEAC consortium, the PEAC Steering Committee and the PEAC Scientific Advisory Board.

In order to ensure effective and efficient administration of the PEAC project, the following administrative infrastructure was installed:

Project Management: to ensure optimal coordination and administration of this programme together with timely and high quality data collection and analysis.

Technical Assistance: A highly experience and able Research Assistant, Miss Rebecca Hands was appointed to ensure efficient processing, storing and high fidelity archiving of PEAC biological samples.

Data Management: A website was created to act as a central repository for all the PEAC project samples and their related data.

Over 300 patients were recruited for the study at Bart's</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genentech</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Roche/Genentech: RA synovial tissue multi-biomic profiling in early arthritis patients</gtr:description><gtr:id>4E860093-7EB3-4D7E-8583-6D4B987A9D7A</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:partnerContribution>Financial support</gtr:partnerContribution><gtr:piContribution>Analysis of samples from PEAC cohort</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Pfizer: Screening Pfizer immunology pipeline against synovial tissue in early RA</gtr:description><gtr:id>26AF8DBC-CBF9-4222-A1D0-9B393A922F45</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:partnerContribution>Financial support, pipeline compounds</gtr:partnerContribution><gtr:piContribution>Analysis of samples from the PEAC cohort</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>PEAC Consortium - Operational</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5250AFFD-0528-4FC4-A2EC-EC0AD01B72CE</gtr:id><gtr:impact>Regular communication to inform partners, monitor progress and to stimulate discussion on future research projects. This included teleconferences, meetings an symposia</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PEAC Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D9BD0FF8-EDB8-4D55-B36B-7631CFFDB12F</gtr:id><gtr:impact>The PEAC Website provides information on the background and objectives of the study. Details of participating centres are included and the sources made available to researchers/industry as a result of the study.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.peac-mrc.mds.qmul.ac.uk/resource.php</gtr:url><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Precision Medicine UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>962E1F9E-EF93-4ABB-8AE2-53589D72DC05</gtr:id><gtr:impact>NOCRI joined UK leaders in the research, development and commercialisation of precision medicine for a one-day event this week designed to encourage new partnerships and highlight new opportunities in the field. The Precision Medicine UK: Collaboration Nation event at De Vere Holborn Bars, London, on 9 December was organised on behalf of the Stratified Medicine Innovation Platform by Innovate UK,, National Institute for Health Research, Cancer Research UK,Medical Research Council, Invest Northern Ireland, Health and Care Research Wales and the Knowledge Transfer Network, with the NIHR Office for Clinical Research Infrastructure (NOCRI) coordinating the NIHR's involvement. The day formed part of a programme to make the UK a world leader in precision medicine and provided real-world examples of the discovery and development of precision medicine solutions, through talks, panel discussions, workshops and exhibitions with the opportunity to arrange one-to-one partnering meetings. Precision medicine is an emerging approach to the treatment and diagnosis of disease that takes into account variations in a patient's genes, environment and lifestyle. It aims to better target treatments to an individual's circumstances to improve outcomes for patients. Representatives from across the NIHR were involved in the day and presented on a range of projects and funding programmes. Professor Bryan Williams of NIHR UCLH Biomedical Research Centre joined the first panel of the day which highlighted UK investments in the invention and evaluation phase of research. Professor Williams' highlighted key NIHR's investments in this space and provided examples of exciting precision medicine projects from UCLH BRC. In addition, a number of NIHR precision medicine projects were presented during the disease area specific showcase sessions. This included Professor Costantino Pitzalis who presented the THERAPIST study on behalf of the NIHR Translational Research Partnership, Professor Simon Mead's who presented a project at NIHR Queen's Square Biomedical Research Unit on the &amp;quot;dementia chip&amp;quot; and Professor Tariq Sadiq's who presented on Capacity Building and Delivery of Precision Medicine in Sexual Health, through NIHR Funding. Mark Samuels, Managing Director of NOCRI, also chaired a discussion panel themed 'Enabling Collaboration', which highlighted the value of collaborative working between companies, academics, charities and patients. The event saw the launch by the chief executive of Innovate UK, Dr Ruth McKernan, of a new map of the precision medicine landscape. A whole range of organisations, including charities, health bodies and devolved administrations are coordinating their work under the umbrella of Innovate UK's Stratified Medicine Innovation Platform, with NOCRI representing the NIHR.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1002635</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR EME funding for R4RA</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC)</gtr:fundingOrg><gtr:fundingRef>11/100/76</gtr:fundingRef><gtr:id>559FDFF6-4848-43D2-B11D-BD455A23EB5A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BMS</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>Bristol-Myers Squibb</gtr:fundingOrg><gtr:fundingRef>IM006-030_Pitzalis</gtr:fundingRef><gtr:id>AAE10058-083B-454F-9BB0-C7F8E454F626</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>993924</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trial - Arthritis Research UK ORBIT Trial- Biopsy driven sub-trial</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>18824</gtr:fundingRef><gtr:id>59BDE3AB-6415-4767-A9F3-8CCC123FB00C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>225000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK Experimental Arthritis Treatment Centre</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20022</gtr:fundingRef><gtr:id>8AD408A1-9515-45F6-AD7A-6FA8039BBB82</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>498438</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Early Arthritis Referral Centre/Barts &amp;amp; the London Charity</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Barts and the London Charity</gtr:fundingOrg><gtr:fundingRef>523/819</gtr:fundingRef><gtr:id>12F7F005-B9D6-4685-97F0-F2CBBDE34E6B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>781220</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Abbvie</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>AbbVie</gtr:fundingOrg><gtr:fundingRef>PO 4200455030</gtr:fundingRef><gtr:id>B043FB1B-EAFB-4069-B600-8C1C0154A4E4</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>252663</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MICA Research Grant &amp;amp; MedImmune Ref: MR/K020250/1 Interleukin-21 (IL-21) in rheumatoid arthritis (RA): exploring its therapeutic potential for the development of a novel targeted biologic therapy.</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9756FC0E-25DA-44A6-8CD0-3DA21D92561D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>713047</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Genentech</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Genentech</gtr:fundingOrg><gtr:fundingRef>PEAC 2</gtr:fundingRef><gtr:id>03B9F9A2-A98F-4AEF-905E-8F9502723F76</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>234612</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>LCRN service support costs and research nurse/North Thames CRN</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>F864173E-6C2C-47DB-9C40-9A5308B423DB</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4985662</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Stratified Medicine</gtr:department><gtr:description>MRC Stratified Medicines _ MATURA</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K015346/1</gtr:fundingRef><gtr:id>4BF396C6-4A65-4CAF-AE55-C211E435217B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>363277</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project grant : Inflammation</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/K013068/1</gtr:fundingRef><gtr:id>36F482F9-AF97-462B-A9DC-501ECF0EE467</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>438000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Janssen</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Janssen Biotech</gtr:fundingOrg><gtr:fundingRef>PO 993320280</gtr:fundingRef><gtr:id>E8370092-CA6C-4583-97C7-0CD66699E36E</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>590980</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>NIHR/ NOCRI Translational Research Partnership (TRP) THERAPIST - Th17 Responses Evaluated in RA Patients on Inhibitors of TNFa</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>57D1D593-31D7-4B42-95F9-1C1B37C9B40F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on Funding Policy: MRC, NIHR, ARUK recognised need to fund Stratified Medicine Programmes in RA. PEAC has formed the platform for a suite of stratified Medicine programmes including MATURA and R4RA</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1B36BD42-BEB0-4CCE-BCC2-1A9140C1D53A</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Translational Research Collaboration for Joint &amp;amp; related inflammatory diseases- Steering Committee Meeting</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>12776444-4A58-4813-A309-F30EF9FAA7D9</gtr:id><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/collaborations-for-early-phase-translational-research/collaborate-with-our-experts-translational-research-partnerships/joint-and-related-inflammatory-diseases-translational-research-partnership.htm</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on Industry drug development policy: Stratified Medicine for RA</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D8208DCF-C408-46EF-85C6-825290342F3E</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Development of immune tolerance therapies for the treatment of rheumatic diseases - THE INNOVATIVE MEDICINES INITIATIVE</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>9FF4F621-19FF-4375-B358-1BAF0A0A459D</gtr:id><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.imi.europa.eu</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Training in Disease Activity Scores &amp;amp; Ultrasound Assessments of RA</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E636FDEC-5F87-4D51-A4EC-A1902EC05997</gtr:id><gtr:impact>Greater consistency in evaluating and recording of measures of disease in RA</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Addressing the grand challenges in Immune Mediated Inflammatory Diseases</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D7700EE5-4EC7-4468-8ABA-09428FFC4F3B</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ACR/eular Exchange Program</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>3738C38B-26A6-4805-B67E-46A982BFC627</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Ultrasound Guided Synovial Biopsy Courses</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>B61BA160-D58D-49BA-BCB5-F4864A671C42</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.matura-mrc.whri.qmul.ac.uk/ultrasound_guided_synovial_biopsy_taking_a_biopsy.php</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EULAR Synovitis Study Group</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>FD62A1E3-8C1F-47B4-A336-A8C33BF4CBD9</gtr:id><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.eular.org/investigative_rheumatology_study_groups.cfm</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>AMP RA SLE Steering Committee</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>D76D9D7C-4604-4493-B59F-7411C215A93B</gtr:id><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>https://www.nih.gov/research-training/accelerating-medicines-partnership-amp</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Annual EATC/EOTC Directors Meeting - Arthritis Research UK</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0C40D588-B79A-4396-A2AD-AC12FA3B2F6E</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Synovial biopsy technique to obtain disease tissue from most patients and any joints (large and small), through a minimally invasive, well-tolerated ultrasound-guided approach. Synovial biopsy B-cell Biomarker as a diagnostic tool to be validated in clinical trials for patient stratification into responsive / non-responsive categories.
(Trained over 20 EU and 15 USA Fellow Rheumatologists 
The diagnostic tool emerging from analysing diseased tissue can be adapted for execution in all NHS accredited clinical pathology units</gtr:description><gtr:id>64C98035-7DF6-46B3-BCC9-FCB1822949E2</gtr:id><gtr:impact>Applied to numerous clinical studies for stratification of RA</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>ORBIT (Biopsy study)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Full Title: A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA
EudraCT reference: 2012-002535-28

R4-RA is a biopsy-driven, multicentre, international, open-label randomised controlled trial. 
This trial will aim to develop a diagnostic tool (immunohistochemical analysis of synovial tissue) for patient stratification into responsive / non-responsive categories with respect to Rituximab therapy in patients who have had an inadequate response to anti-TNF therapy. Specifically, it aims to determine whether a diagnostic synovial biopsy showing a B-cell &amp;quot;rich/poor pathotype&amp;quot; defines specific disease responsive/resistant subsets for patient stratification and helps rationalize biologic drug choice.

Patients will undergo a synovial biopsy which will stratify them in to 3 pathotype groups (B Cell Poor, B Cell Rich, Germinal Centres (GC) Rich) according to the B-cell score from the biopsy tissues, and in each stratum they will be randomised into two therapeutic arms, Rituximab and Tocilizumab (1:1). Primary Endpoint is treatment response assessed using the Clinical Disease Activity Index (CDAI) at 16 weeks. Patients deemed treatment failures at 16 weeks will be switched to the other therapeutic option. The trial involves 48 weeks treatment period, followed by further 48 weeks follow-up period. 

Both Rituximab and Tocilizumab have marketing authorisation. Whilst Rituximab is a NICE approved treatment option for patients following anti-TNF therapy, Tocilizumab is not currently a NICE approved pathway.
The trial is funded by NIHR EME Programme.</gtr:description><gtr:id>AD08DC2B-C356-4632-A8FF-4A8E5A33C7E9</gtr:id><gtr:impact>The significant impact is expected from the outcome of this trial, which has a potential to change clinical practice and therapeutic algorithms for biologic therapies in Rheumatoid Arthritis (RA).

This trial aims to develop of a diagnostic synovial tissue biopsy for patient stratification into responsive / non-responsive categories (treatment algorithm) to the depleting anti-CD20 monoclonal antibody: Rituximab (RTX).
As approximately half of the RA patients have very few B-cells in the joint, the hypothesis of this trial is that these patients are less likely to respond to RTX and that, by examining a small piece of synovial tissue (biopsy) for the presence or absence of B cells prior to treatment with RTX, clinicians will be able to predict likelihood of response and inform drug choice. 

This would: a) provide better care by preventing delay in starting a potentially more effective biologic drug; b) prevent unnecessary exposure to a potentially seriously toxic drug such as RTX and c) avoid wasting &amp;pound;6-8 million to the NHS.

The development of the technology may also lead to protectable IP.

In addition, transcriptomic and next generation sequencing analysis may lead to the identification of specific pathways, &amp;quot;known or unknown&amp;quot;, associated with clinical response to therapeutic intervention with biologic agents. The discovery of such pathways would lead to patentable inventions.</gtr:impact><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Though anti-TNFa therapy has transformed the treatment of rheumatoid arthritis (RA), 30-40% patients don't respond to this treatment. Currently, there are no tests capable of predicting response and the mechanisms of non-response remain unknown. This leaves a major unmet need and a considerable health and economic burden. In the UK alone, RA drugs cost the NHS &amp;pound;560 million, while RA total annual economic impact is estimated &amp;pound;4.2 billion (NAO). The THERAPIST study aims to address this major unmet need by exploring the capacity of disease tissue (synovium) and peripheral blood biomarkers to predict response prior to anti-TNFa therapy initiation and to understand the mechanisms of response/nonresponse. In addition THERAPIST will characterise the role of IL17/ Th17 pathway (primary hypothesis) &amp;amp; , through a powerful hypothesis-free discovery investigation, potentially unveil new therapeutic targets. 50 RA patients requiring anti-TNFa therapy after failure of conventional Disease Modifying Anti Rheumatic Drugs, e.g. methotrexate, according to NICE guidelines, will be recruited to the study following informed consent. Clinical responses will be assessed by standard/validated tools such as 28 tender-swollen joint count integrated into the Disease Activity Score (DAS28), as well as objective ultrasound joint imaging. Biological responses are measured in the disease tissue (synovial biopsy substudy) in 20 patients consenting to an ultrasound-guided, minimally invasive, well-tolerated procedure, as we described (Kelly et al. Ann Rheum Disease 2013) and in peripheral blood of all 50 patients as comparators. The biopsy substudy is essential to provide disease tissue for the proposed investigation, as 30 years of research looking for peripheral blood predictive biomarkers have proven unsuccessful. It is clear that direct sampling of the diseased tissue can provide fundamental evidence to inform therapeutic decision-making (e.g. Tamoxifen in ER+ve breast cancer).</gtr:description><gtr:id>7ED63C70-2E08-4284-99F1-69D23AAC4FE4</gtr:id><gtr:impact>Provide evidence to evidence to inform therapeutic decision-making so improving health outcomes and reducing the economic burden of RA</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Therapist</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=18893</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>This study will aim to test the utility of synovial histopathology and cell type as a potential biomarker to guide therapeutic decisions in RA patients failing DMARD therapy and started on Rituximab, Tocilizumab or Etanercept therapy. 
Specifically, can a diagnostic synovial biopsy showing a B-cell &amp;quot;rich/poor pathotype&amp;quot; define specific disease responsive/resistant subsets for patient stratification and help rationalise biologic drug choice? 
The trial is currently under review by the REC and MHRA and is jointly funded by the MRC and ARUK.</gtr:description><gtr:id>ABFACCC6-499C-4086-9EC5-16D6BA14C0F9</gtr:id><gtr:impact>The aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy. The following are notable impacts arising from trial development:

1. STRAP Protocol complete and patient related documents review by Queen Mary patient advisory group.
3. Clinical Database: testing underway.
4. REC and MHRA submitted. REC meeting 13th Nov 5. 
5. TMG formed and convenes frequently TSC will be in line with timelines. 
6. STRAP website launched.
7. Investigators Meeting 17th September 2014.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Stratification of Therapy for Rheumatoid Arthritis by Pathobiology (STRAP) Clinical Trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.matura-mrc.whri.qmul.ac.uk</gtr:url><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The first comprehensive synovial RNA-sequence transcriptomic database</gtr:description><gtr:id>EE898062-E3D7-490B-85AB-1DCCA7E9F04E</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Synovial RNA-sequence transcriptomic database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Study specific Electronic Data Capture (EDC) system for PEAC. This includes a electronic Case Record Form (eCRF) as well as a Study Management system linking clinical data to pathobiology data. The EDC system is designed to follow the order of the study assessments and include all the clinical data (incl. Medication history, lifestyle factors questionnaire, DAS28 etc) submission to the database is via an encrypted and password protected link dedicated to each individual centre. This database is designed to provide an online facility to monitor registration, transport and processing of PEAC samples, from the clinic to the microscope. Further, this application allows the clinician at a remote centre, to view histopathology reports and representative micrographs of submitted samples as soon as they are prepared at the central repository. Additionally, a PEAC Website Tutorial Manual has been constructed and disseminated to the participating PEAC centres. This manual details online access to the PEAC Bio-bank and tracking of the samples provided to PEAC.</gtr:description><gtr:id>A07C26D8-EC13-4E7E-A06E-1C5AA5CEE088</gtr:id><gtr:impact>High quality data for PEAC cohort now supporting many studies</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PEAC Study Database</gtr:title><gtr:type>Data handling &amp; control</gtr:type><gtr:url>https://www.peac.whri.qmul.ac.uk</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>EMR biobank containing over 800 synovial biopsies supports multiple projects and each research project adds to the samples and information available 

Synovial biopsies are linked to tight clinical databases including ultrasound synovitis assessments</gtr:description><gtr:id>D5968C7C-E9E1-4118-A68D-48EE679893DB</gtr:id><gtr:impact>Supports academic and industry collaborations</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EMR Biobank</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Blood, urine and synovial tissue coupled with detailed clinical phenotyping</gtr:description><gtr:id>9D325F92-9BD1-46FE-B383-6AB403234ED5</gtr:id><gtr:impact>The PEAC biomedical resource will enable to examine the role of multiple cellular and molecular pathways involved in arthritis susceptibility, heterogeneous outcome and treatment response.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Pathobiology of Early Arthritis Cohort (PEAC)</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.peac-mrc.mds.qmul.ac.uk/</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F6D2EDFA-8D78-4334-83D8-DAA807A7EC2F"><gtr:id>F6D2EDFA-8D78-4334-83D8-DAA807A7EC2F</gtr:id><gtr:title>High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a60d94cc3ed6c05e01fa73033f1a9896"><gtr:id>a60d94cc3ed6c05e01fa73033f1a9896</gtr:id><gtr:otherNames>Bugatti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31D99EDE-74D4-48E2-9462-F3C295ED50D7"><gtr:id>31D99EDE-74D4-48E2-9462-F3C295ED50D7</gtr:id><gtr:title>Pathogenesis of rheumatoid arthritis: from systemic autoimmunity to localised joint disease.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/60252eafff9d9abc3b97c7eaf2645a50"><gtr:id>60252eafff9d9abc3b97c7eaf2645a50</gtr:id><gtr:otherNames>Pitzalis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BCDFBE83-AA15-49B7-9BB6-A319D63F4B25"><gtr:id>BCDFBE83-AA15-49B7-9BB6-A319D63F4B25</gtr:id><gtr:title>Angiogenic gene expression and vascular density are reflected in ultrasonographic features of synovitis in early Rheumatoid Arthritis: an observational study.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f63e49e0365865469c963d1bef8f1eca"><gtr:id>f63e49e0365865469c963d1bef8f1eca</gtr:id><gtr:otherNames>Kelly S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9727E03F-B4ED-44F8-AF0C-CE3080E8BFC0"><gtr:id>9727E03F-B4ED-44F8-AF0C-CE3080E8BFC0</gtr:id><gtr:title>Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements.</gtr:title><gtr:parentPublicationTitle>The Journal of rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e207d7f627ccf2bca8964f0049ea4196"><gtr:id>e207d7f627ccf2bca8964f0049ea4196</gtr:id><gtr:otherNames>Humby F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0315-162X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A0DE813-8B21-483C-9E1D-8F3A4DA1F63A"><gtr:id>7A0DE813-8B21-483C-9E1D-8F3A4DA1F63A</gtr:id><gtr:title>FRI0043 Synovial Mast Cells Correlate with Local and Systemic Inflammation and Are Functionally Associated with Ectopic Lymphoid Structures in Patients with Early Rheumatoid Arthritis</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/362a378496300df00ddd4a3655a2d1aa"><gtr:id>362a378496300df00ddd4a3655a2d1aa</gtr:id><gtr:otherNames>Rivellese F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9430C9F6-6EE1-4FEC-A594-6D5835222D83"><gtr:id>9430C9F6-6EE1-4FEC-A594-6D5835222D83</gtr:id><gtr:title>Ultrasound-guided synovial biopsy of the wrist does not alter subsequent clinical or ultrasound disease activity assessments: a prospective study for incorporation of imaging in clinical trials.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ff9f665f317638f8bfd7607e1eb587d"><gtr:id>6ff9f665f317638f8bfd7607e1eb587d</gtr:id><gtr:otherNames>Lazarou I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0392-856X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A84E1204-59BE-46FF-8B73-04AABF943DC0"><gtr:id>A84E1204-59BE-46FF-8B73-04AABF943DC0</gtr:id><gtr:title>Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07da5777d91efb85fe2471dfc244d0bf"><gtr:id>07da5777d91efb85fe2471dfc244d0bf</gtr:id><gtr:otherNames>Croia C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/97A6D30D-623D-4B90-8E1A-94CE7D171A91"><gtr:id>97A6D30D-623D-4B90-8E1A-94CE7D171A91</gtr:id><gtr:title>Reply.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/362a378496300df00ddd4a3655a2d1aa"><gtr:id>362a378496300df00ddd4a3655a2d1aa</gtr:id><gtr:otherNames>Rivellese F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CC7768A-4724-441F-87B0-F16824306CD9"><gtr:id>4CC7768A-4724-441F-87B0-F16824306CD9</gtr:id><gtr:title>Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/362a378496300df00ddd4a3655a2d1aa"><gtr:id>362a378496300df00ddd4a3655a2d1aa</gtr:id><gtr:otherNames>Rivellese F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3DCF89EF-66E8-4D2A-9A20-664BEBDA1FCE"><gtr:id>3DCF89EF-66E8-4D2A-9A20-664BEBDA1FCE</gtr:id><gtr:title>Ectopic lymphoid neogenesis in rheumatic autoimmune diseases.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/be82894edbca58453cb3f244f0a28171"><gtr:id>be82894edbca58453cb3f244f0a28171</gtr:id><gtr:otherNames>Bombardieri M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DCE1A571-6E5A-49A4-8FCB-51ACC592D4BF"><gtr:id>DCE1A571-6E5A-49A4-8FCB-51ACC592D4BF</gtr:id><gtr:title>Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9fc9cdf05dee98ba5676331d9b39a2fd"><gtr:id>9fc9cdf05dee98ba5676331d9b39a2fd</gtr:id><gtr:otherNames>Corsiero E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0DEB4F01-E1CE-407B-A86B-2B539791927E"><gtr:id>0DEB4F01-E1CE-407B-A86B-2B539791927E</gtr:id><gtr:title>Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6bfa17a1651cb9de1c510b50b22414e"><gtr:id>d6bfa17a1651cb9de1c510b50b22414e</gtr:id><gtr:otherNames>Seymour MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/895FDB65-0455-4ADB-BA58-591B6D21CF80"><gtr:id>895FDB65-0455-4ADB-BA58-591B6D21CF80</gtr:id><gtr:title>Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d6a7ee0f691937e2d7656b89816d236"><gtr:id>3d6a7ee0f691937e2d7656b89816d236</gtr:id><gtr:otherNames>Komarowska I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38E4251C-D48D-45C0-BFA1-05ED04829E34"><gtr:id>38E4251C-D48D-45C0-BFA1-05ED04829E34</gtr:id><gtr:title>Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb4f1e8c0a6c1979027a09dcd792a65e"><gtr:id>cb4f1e8c0a6c1979027a09dcd792a65e</gtr:id><gtr:otherNames>Jones GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A0BECDA-F0FC-49AE-AFC3-DFB8EECCF87F"><gtr:id>3A0BECDA-F0FC-49AE-AFC3-DFB8EECCF87F</gtr:id><gtr:title>New learnings on the pathophysiology of RA from synovial biopsies.</gtr:title><gtr:parentPublicationTitle>Current opinion in rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/60252eafff9d9abc3b97c7eaf2645a50"><gtr:id>60252eafff9d9abc3b97c7eaf2645a50</gtr:id><gtr:otherNames>Pitzalis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1040-8711</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/63DEDA4E-053B-4929-B3B8-7BF20E2C2282"><gtr:id>63DEDA4E-053B-4929-B3B8-7BF20E2C2282</gtr:id><gtr:title>Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e207d7f627ccf2bca8964f0049ea4196"><gtr:id>e207d7f627ccf2bca8964f0049ea4196</gtr:id><gtr:otherNames>Humby F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FAC4B9A-DCC0-4A7F-85EA-4EBFD248AB50"><gtr:id>9FAC4B9A-DCC0-4A7F-85EA-4EBFD248AB50</gtr:id><gtr:title>Higher expression of TNFa-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/169a0a601c75ec1aa84426eef7889fbe"><gtr:id>169a0a601c75ec1aa84426eef7889fbe</gtr:id><gtr:otherNames>De Groof A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/80C5B649-E66F-4ACB-8FB3-21A79970E766"><gtr:id>80C5B649-E66F-4ACB-8FB3-21A79970E766</gtr:id><gtr:title>Peripheral and synovial mechanisms of humoral autoimmunity in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9fc9cdf05dee98ba5676331d9b39a2fd"><gtr:id>9fc9cdf05dee98ba5676331d9b39a2fd</gtr:id><gtr:otherNames>Corsiero E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D2444291-13A8-4E90-BC16-1E59825B8445"><gtr:id>D2444291-13A8-4E90-BC16-1E59825B8445</gtr:id><gtr:title>Ultrasound-guided synovial biopsy: a systematic review according to the OMERACT filter and recommendations for minimal reporting standards in clinical studies.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ff9f665f317638f8bfd7607e1eb587d"><gtr:id>6ff9f665f317638f8bfd7607e1eb587d</gtr:id><gtr:otherNames>Lazarou I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9EB0C5D1-5983-4E90-A07B-BF7F733AFE91"><gtr:id>9EB0C5D1-5983-4E90-A07B-BF7F733AFE91</gtr:id><gtr:title>Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32521864ce435cacd21409682920dae0"><gtr:id>32521864ce435cacd21409682920dae0</gtr:id><gtr:otherNames>El Shikh ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1EF5A7BA-546B-4426-BC97-FC88A2FFEB74"><gtr:id>1EF5A7BA-546B-4426-BC97-FC88A2FFEB74</gtr:id><gtr:title>Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f63e49e0365865469c963d1bef8f1eca"><gtr:id>f63e49e0365865469c963d1bef8f1eca</gtr:id><gtr:otherNames>Kelly S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/625604B8-281F-4DC2-A810-26588C8D329C"><gtr:id>625604B8-281F-4DC2-A810-26588C8D329C</gtr:id><gtr:title>Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9fc9cdf05dee98ba5676331d9b39a2fd"><gtr:id>9fc9cdf05dee98ba5676331d9b39a2fd</gtr:id><gtr:otherNames>Corsiero E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2ABC4873-7BD0-4CA0-841A-2D8F5934856B"><gtr:id>2ABC4873-7BD0-4CA0-841A-2D8F5934856B</gtr:id><gtr:title>Ectopic Lymphoid Structures: Powerhouse of Autoimmunity.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9fc9cdf05dee98ba5676331d9b39a2fd"><gtr:id>9fc9cdf05dee98ba5676331d9b39a2fd</gtr:id><gtr:otherNames>Corsiero E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800648</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>